Analysis updated on Oct. 15, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Bone Biologics Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for BBLG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BBLG included.
Follow BBLG free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
| Metric | BBLG | Rank |
|---|---|---|
| EPS | $-1.43 | – |
| Metric | BBLG | Rank |
|---|---|---|
| ROE | -73.7% | 12/20 |
| ROA | -65.2% | 17/20 |
| ROIC | -78.0% | 18/21 |
| Metric | BBLG | Rank |
|---|---|---|
| Current Ratio | 8.67x | 3/24 |
| D/E Ratio | 0.13x | 22/23 |
| Financial Leverage | 1.13x | 22/23 |
| Interest Coverage | -3543.3x | 21/21 |
| Working Capital | $4M | 19/22 |
| Metric | BBLG | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 14/22 |
| Metric | BBLG | Rank |
|---|---|---|
| Operating Income | -$3M | 10/22 |
| Net Income | -$2M | 8/18 |
| R&D Expense | $900K | 16/19 |
| Metric | BBLG | Rank |
|---|---|---|
| EPS Growth | -344.9% | – |
| Total Current Assets | $4M | |
| Cash & Short-term Investments | $4M | |
| Total Liabilities | $510K | |
| Short-term Debt | $0.00M |
Companies classified under the same SEC industry code as Bone Biologics Corp (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BBLG Bone Biologics Corp | ▲ | N/A |
| ISRG Intuitive Surgical Inc | ▼ | $148.46B |
| SNN Smith & Nephew Plc | ▼ | $24.47B |
| STE Steris Plc | ▼ | $21.18B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $17.50B |
| ALGN Align Technology Inc | ▶ | $10.26B |
| MSA Msa Safety Inc | ▼ | $7.00B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.72B |
| CDRE Cadre Holdings, Inc. | ▲ | $1.10B |
| ENOV Enovis Corp | ▶ | $1.07B |
| AVR Anteris Technologies Global Corp. | ▼ | $610M |
| SMTI Sanara Medtech Inc. | ▼ | $323M |
| INGN Inogen Inc | ▶ | $163M |
| LAKE Lakeland Industries Inc | ▲ | $92M |
| NTRB Nutriband Inc. | ▲ | $77M |
| APT Alpha Pro Tech Ltd | ▲ | $57M |
| COCH Envoy Medical, Inc. | ▲ | $49M |
| MYO Myomo, Inc. | ▲ | $49M |
| MLSS Milestone Scientific Inc. | ▲ | $30M |
| LFWD Lifeward Ltd. | ▲ | $18M |
| UEEC United Health Products, Inc. | ▶ | $12M |
| RGNT Regentis Biomaterials Ltd. | ▶ | $8M |
| CLGN Collplant Biotechnologies Ltd | ▲ | $5M |
| FEED Envue Medical, Inc. | ▼ | $470K |
| RBOT Vicarious Surgical Inc. | ▶ | $360K |
| CUPR Cuprina Holdings (Cayman) Ltd | ▼ | N/A |
| LGMK Logicmark, Inc. | ▶ | N/A |
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the ...
BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, ...
Matt Liteplo: Hello, and welcome to Virtual Investor Conferences. My name is Matt Liteplo, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you have joined us ...
Our AI ranks Bone Biologics Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for BBLG is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Bone Biologics Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
27 issuers in our coverage, BBLG included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Smith & Nephew Plc (SNN), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.